| Companies sponsors |
Johnson and Johnson (amivantamab, lazertinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Asthma and Lung UK |
| |
Black Health Agency for Equality |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Cancer52 |
| |
EGFR Positive UK |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
Oncogene-Driven Lung Cancer Patient Alliance |
| |
Roy Castle Lung Cancer Foundation |
| |
Ruth Strauss Foundation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| |
UK Lung Cancer Coalition |
| Professional groups |
Association of Anaesthetists |
| |
Association of Cancer Physicians |
| |
Association of Respiratory Nurse Specialists |
| |
Association of Surgeons of Great Britain and Ireland |
| |
British Geriatrics Society |
| |
British Institute of Radiology |
| |
British Oncology Pharmacy Association |
| |
British Psychosocial Oncology Society |
| |
British Society of Interventional Radiology |
| |
British Thoracic Oncology Group |
| |
British Thoracic Society |
| |
British Transplantation Society |
| |
Cancer Research UK |
| |
Lung Cancer and Mesothelioma Clinical Expert Group |
| |
Lung Cancer Nursing UK |
| |
National Heart and Lung Institute |
| |
NHS Blood and Transplant |
| |
Primary Care Respiratory Society |
| |
Royal College of Anaesthetists |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiographers |
| |
UK Clinical Pharmacy Association |
| |
UK Oncology Nursing Society |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Amarox (erlotinib) |
| |
AstraZeneca (gefitinib, osimertinib) |
| |
Boehringer Ingelheim (afatinib) |
| |
Cipla EU (gefitinib) |
| |
Genus Pharmaceuticals (gefitinib) |
| |
Glenmark Pharmaceutical (erlotinib) |
| |
Mylan (erlotinib) |
| |
Pfizer (dacomitinib) |
| |
Roche (erlotinib) |
| |
Sandoz (erlotinib, gefitinib) |
| |
Zentiva (erlotinib) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Lung Cancer Group |
| |
Cochrane UK |
| |
Genomics England |
| |
Institute of Cancer Research |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |